Inclusion Criteria:

- Pre-menopausal adult women with a diagnosis of moderate or severe symptoms of uterine
fibroids who are initiating treatment with ESMYA.

Exclusion Criteria:

- Patient is pregnant or plans to become pregnant in the next 3 months,

- Patient is breastfeeding,

- Patient has genital bleeding of unknown etiology or not due to uterine fibroids,

- Patient has been diagnosed with uterine, cervical, ovarian or breast cancer,

- Patient is using an investigational drug/therapy or has discontinued the use of an
investigational drug/therapy within 30 days prior to study enrollment,

- Patient has hypersensitivity to the active substance of ESMYA or to one of its
excipients